BR112022024033A2 - Formulações e métodos para o tratamento de síndrome do desconforto respiratório agudo, asma, ou rinite alérgica - Google Patents

Formulações e métodos para o tratamento de síndrome do desconforto respiratório agudo, asma, ou rinite alérgica

Info

Publication number
BR112022024033A2
BR112022024033A2 BR112022024033A BR112022024033A BR112022024033A2 BR 112022024033 A2 BR112022024033 A2 BR 112022024033A2 BR 112022024033 A BR112022024033 A BR 112022024033A BR 112022024033 A BR112022024033 A BR 112022024033A BR 112022024033 A2 BR112022024033 A2 BR 112022024033A2
Authority
BR
Brazil
Prior art keywords
asthma
allergic rhinitis
treatment
formulations
methods
Prior art date
Application number
BR112022024033A
Other languages
English (en)
Portuguese (pt)
Inventor
Vidyasagar Sadasivan
Grosche Astrid
Xu Xiaodong
Angoli Damiano
J Gatto Stephen
Original Assignee
Univ Florida
Entrinsic Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida, Entrinsic Llc filed Critical Univ Florida
Publication of BR112022024033A2 publication Critical patent/BR112022024033A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022024033A 2020-05-29 2021-05-28 Formulações e métodos para o tratamento de síndrome do desconforto respiratório agudo, asma, ou rinite alérgica BR112022024033A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063032185P 2020-05-29 2020-05-29
US202063080470P 2020-09-18 2020-09-18
US202063088813P 2020-10-07 2020-10-07
US202163136404P 2021-01-12 2021-01-12
PCT/US2021/034807 WO2021243183A1 (en) 2020-05-29 2021-05-28 Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis

Publications (1)

Publication Number Publication Date
BR112022024033A2 true BR112022024033A2 (pt) 2022-12-20

Family

ID=78722883

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024033A BR112022024033A2 (pt) 2020-05-29 2021-05-28 Formulações e métodos para o tratamento de síndrome do desconforto respiratório agudo, asma, ou rinite alérgica

Country Status (10)

Country Link
US (1) US20230201151A1 (enExample)
EP (1) EP4157218A4 (enExample)
JP (1) JP2023531872A (enExample)
KR (1) KR20230018474A (enExample)
CN (1) CN115697301A (enExample)
AU (1) AU2021280328A1 (enExample)
BR (1) BR112022024033A2 (enExample)
CA (1) CA3177780A1 (enExample)
MX (1) MX2022015044A (enExample)
WO (1) WO2021243183A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116036277B (zh) * 2022-07-19 2023-10-31 广州国家实验室 氯离子在预防、治疗冠状病毒所致疾病中的应用
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686340B2 (en) * 2001-06-19 2004-02-03 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells
CN104207146A (zh) * 2014-07-26 2014-12-17 胡安然 呼吸系统疾病全营养配方食品
WO2019070759A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation Incorporated AMINO ACID COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
US12109191B2 (en) * 2017-10-02 2024-10-08 Amilyfe, Llc Materials and methods for inhibiting tumor growth
EP3873453A4 (en) * 2018-10-30 2022-08-03 University of Florida Research Foundation, Incorporated AMINO ACID COMPOSITIONS AND METHODS OF TREATMENT OF CF

Also Published As

Publication number Publication date
MX2022015044A (es) 2023-01-04
EP4157218A4 (en) 2024-06-26
WO2021243183A1 (en) 2021-12-02
WO2021243183A8 (en) 2022-01-13
EP4157218A1 (en) 2023-04-05
AU2021280328A1 (en) 2022-11-17
JP2023531872A (ja) 2023-07-26
US20230201151A1 (en) 2023-06-29
CA3177780A1 (en) 2021-12-02
KR20230018474A (ko) 2023-02-07
CN115697301A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
BR112017023380A2 (pt) sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo.
BR112021023814A2 (pt) Inibidores de proteases de cisteína e métodos de uso das mesmas
WO2017163132A3 (en) Use of umbilical cord blood derived exosomes for tissue repair
MX2012002216A (es) Nueva endolisina obpgplys.
BR112022016550A2 (pt) Proteínas de ligação a flt3 e métodos de uso
BR112013010844A2 (pt) nova endolisina
BR112019008975A2 (pt) variantes de superfície celular imunologicamente discerníveis para uso em terapia celular
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
MX2019011808A (es) Endolisinas de gram-negativas modificadas.
BR112013026032A2 (pt) composições nutricionais incluindo ácidos graxos de cadeia ramificada para cicatrização de ferida
NO20064584L (no) Tetrahydropyridoindolderivater
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
BRPI1010861A8 (pt) métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica
BR112017015773A2 (pt) muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo
BR112022004047A2 (pt) Proteínas de ligação multiespecíficas para o tratamento de câncer
MX2022003758A (es) Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido.
BR112022013204A2 (pt) Usos de uma composição e de uma preparação combinada
BR112015019568A2 (pt) Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
MY200841A (en) Influenza Virus Vaccines and Uses Thereof
BR112017018209A2 (pt) produtos terapêuticos de polipeptídeo e usos dos mesmos
MX2022002766A (es) Vacunas contra el virus de la gripe y usos de las mismas.
BR112022018586A2 (pt) Derivados de ácido borônico e usos terapêuticos dos mesmos
EA201991015A1 (ru) Модифицированные пептиды

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements